14 - Seizure Disorders Flashcards

1
Q

Define seizure

A

Abnormal, paroxysmal, excessive firing of CNS neurons – transient event

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Define epilepsy

A

Chronic condition characterized by recurrent seizures which aren’t provoked by systemic or acute neurologic insults

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Define status epilepticus

A

Seizure lasting >/ 30 minutes or >/ 2 sequential seizures w/o return to normal mental baseline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Initial evaluation of seizure

A
  • When pt presents w/ first seizure, need to rule out physiologic (and possibly treatable) causes before beginning therapy for seizure disorder, or epilepsy
  • This evaluation will help determine the likelihood of future seizures and assist w/ deciding if anti-seizure therapy is warranted
  • Hx and physical exam, lab tests (CBC, electrolytes, glucose, hepatic and renal function, etc.), blood/urine tox screen for drugs (to rule out provoked seizure), EEG, CT/MRI to rule out brain tumour or bleeding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Diagnosing epilepsy

A
  • At least 2 unprovoked (or reflex) seizures occurring > 24 h apart
    • Unprovoked = a cause that we can’t fix
  • Can also diagnose after 1 seizure based on px hx & risk factors (> 60% chance of having another seizure)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Types of seizures

A
  • Focal = seizure activity starts in one area of the brain
  • Generalized = seizure activity involves both hemispheres of the brain
  • Tonic = stiff/flexed; tend to fall backwards
  • Clonic = convulsions
  • Myoclonic = short muscle twitches
  • Atonic = relaxed; tend to fall forward
  • Tonic-clonic = tonic phase + clonic phase (alternates between flexion and convulsion)
  • Absence = “spaced out”
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Physiology applicable to seizures

A
  • In normal synaptic transmission, there is a balance between inhibitory and excitatory transmission
  • Inhibitory = GABA binds to post-synaptic GABAa receptor to open Cl- ion channels & allow influx (hyperpolarized postsynaptic neuron = less likely to “fire”)
  • Excitatory = glutamate binds to glutamate receptor (NMDA or non-NMDA type); net result is excitatory postsynaptic potential (ready to “fire)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Target for most anti-epileptic drugs (AEDs)

A
  • Enhanced excitation (glutamate)
  • Membrane depolarization (affecting ion channel Na+, Ca2+, K+ currents)
  • Reduced inhibition (GABA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Goals of therapy for seizure disorders

A
  • Eliminate seizures (reduce frequency and severity)
  • Minimize side effects
  • Optimize QOL – address comorbid anxiety, depression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Natural hx of treated epilepsy

A
  • 60-65% are seizure free (most are w/ one drug but some require more than one)
  • Remission: complete cessation of seizures (seizure-free) for at least 1 year
  • 30-40% are not controlled
  • Refractory: 2 or more AEDs failed to control seizures (appropriate drug, appropriately dosed, tolerated)
  • *Majority of px are controlled w/ their first monotherapy, but some require second or third monotherapy or more than 1 drug simultaneously
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

General principles for tx of seizure disorders

A
  • Verify diagnosis and determine etiology if possible
  • Review seizure description to ensure correct classification
  • Match choice of AED to seizure type and to specific pt
  • Use monotherapy if possible; polytherapy if necessary
  • When adding an AED start low and go slow, but if needed push to max tolerated dose
  • Consider changing the timing of dosing to reduce toxicity
  • Use clinical response and PK principles to fine-tune dose
  • Adjust doses for drug-drug interactions (**AEDs have many interactions)
  • Don’t give up
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Justifying your selection fo AED **know this

A
  • Is a drug indicated? (if pt is diagnosed w/ epilepsy)
  • Is the selected drug effective? – evidence vs. clinical experience
  • Is the selected drug safe? – most common/ serious SE, drug interactions, comorbidities
  • Is the selected drug convenient? – available, affordable, relatively easy to take
    • Do you have money to pay for this if it isn’t covered?
    • Are you likely to remember to take this medication every day?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How to determine if an AED is indicated for a pt

A
  • Generally, once a pt meets the criteria for diagnosis of epilepsy tx is indicated
  • Clinical decision process to treat first-time unprovoked seizures not diagnosed as epilepsy is very pt specific and depends on multiple clinical factors
  • Weigh risk of seizure recurrence against adverse effects of AEDs (and consider pt preferences)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Recommended drug therapy for different seizure types to know**

A
  • Focal (adult) – carbamazepine, levetiracetam, valproic acid
  • Generalized tonic-clonic (adult) – carbamazepine, lamotrigine, oxcarbazepine, valproic acid
  • Absence (children) – ethosuximide, valproic acid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Most common SEs for all AEDs

A
  • CNS side effects
    • Drowsiness, sedation, fatigue
    • Incoordination
    • Dizziness
    • Cognitive impairment (mental dulling, memory, concentration)
    • Diplopia (double vision)
  • *May be comparatively worse w/ phenobarbital, carbamazepine, & topiramate
  • GI side effects -> diarrhea, cramping
  • Toxicities are additive (ie: worse w/ each additional AED added)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Dose related SE of AEDs

A
  • Associated w/ AED initiation or dose increase
  • Usually corelate w/ blood concentration
  • Reversible on lowering or discontinuing AED
  • Predictable – AED selection based on SE profile
17
Q

Some examples of dose related SEs of AEDs

A
  • Carbamazepine -> benign leukopenia
  • Valproic acid -> GI, benign elevation of liver enzymes, weight gain, hair loss, hirsutism
  • Topiramate -> weight loss, mood changes
18
Q

AED idiosyncratic reactions

A
  • More serious and potentially life-threatening
  • Not dose-related
  • No lab test/ level identifies risk for these reactions
  • Risk factors = hx of previous drug reactions, liver/kidney function, conditions affecting hematopoiesis, metabolic disorders
  • Mechanism of reaction:
    • Immune-mediated reaction to the drug
    • Genetics – unusual sensitivity to drug
  • *Less likely w/ gabapentin, pregabalin, topiramate, oxcarbazepine, and levetiracetam
19
Q

Hypersensitivity reactions to AEDs

A
  • Rare, idiosyncratic reactions that can be life threatening – SJS, TEN (toxic epidermal necrosis), DRESS (drug rash w/ eosinophilia and systemic sx)
  • SJS and TEN most often associated w/ carbamazepine, oxcarbazepine, lamotrigine; less w/ VPA and topiramate
  • Highest risk of occurrence during first 2 months of therapy
20
Q

Other idiosyncratic reactions from AEDs

A
  • Agranulocytosis (rare w/ carbamazepine)
  • Aplastic anemia (VPA, CBZ)
  • Hepatotoxicity (VPA)
  • *Increased suicide risk (especially w/ other psych conditions)
21
Q

AED considerations in pregnancy**

A
  • *Never use VPA in pregnancy or women of child bearing age
  • Greater risk of malformation and possible neurodevelopmental impairment w/ VPA
  • VPA has highest risk of teratogenicity and neurodevelopmental outcomes than any other seizure med
  • All females on AEDs should receive folic acid before any possibility of pregnancy
22
Q

Drug interactions w/ AEDs

A
  • CYP P450 inducers = carbamazepine, phenytoin, phenobarbital, topiramate, oxcarbazepine
    • Results in increased drug metabolism of drug metabolized by the same pathway = reduced plasma concentrations & altered pharmacologic effect (ex: warfarin, oral contraceptives)
  • CYP P450 inhibitor = valproate
    • Results in decreased drug metabolism of drug metabolized by the same pathway = increased plasma concentrations (and potential increases in toxicity)
  • *Drugs less likely to interact = gabapentin, levetiracetam
23
Q

Serum level monitoring for AEDs

A
  • *Only done if clinically indicated
  • To assess non-adherence
  • Suspected toxicity
  • Management of PK interactions
  • Special clinical conditions = status epilepticus, organ failure, pregnant while on lamotrigine or phenytoin (levels affected by pregnancy)
  • Used as a guide rather than rule for clinical decision making; therapeutic and toxic ranges are individualized
24
Q

Pt counselling on new AEDs **know this

A
  • Will the drug work? – probability of efficacy
  • *How will they assess efficacy? – record seizure frequency (so efficacy can be quantified and compared among AEDs)
  • Will they tolerate it? – be open about SEs & discuss titration; develop monitoring plan; pt to document adverse effects on a calendar/ journal
  • Non-pharm interventions? – record precipitating factors (ex: menses, sleep, stress)
  • Monitoring required? – blood work (CBC, electrolytes, LFTs) before starting AED and regular intervals during first months of use
25
Q

Managing adverse effects of AEDs

A
  • Factors affecting tolerability and safety:
    1. Dose escalation rate (too fast = SE risk)
    2. Habituation period (time to allow adverse effects to occur – varies btwn px)
    3. Blood levels (rate of increase, peaks)
    4. Timing of doses (single vs. spread out vs. ER formulation)
    5. PK interactions (drug interactions – change in metabolism)
    6. PD interactions (additive or synergistic adverse effects)
26
Q

SE management strategies for new AEDs

A
  • Use a test dose HS
  • If SE, delay next dose
  • If SE recur, reduce dose
  • Increase dose as tolerated
27
Q

SE management strategies for peak blood levels of AEDs

A
  • Administer w/ food (to slow rate of absorption)
  • Change dosing interval
  • Give larger dose at bedtime, smaller doses during the day
  • XR formulation if available
28
Q

SE management strategies for PK interactions of AEDs

A
  • Adjust co-therapy (ex: reduce dose of one drug)

- Gradual dose escalation

29
Q

SE management strategies for PD interactions of AEDs

A

Reduce co-therapy if possible or change to an alternative therapy w/ fewer additive SEs

30
Q

Approach to managing recurrence

A
  • Includes evaluation for progressive pathology and avoidable precipitant (stress, sleep, hypoglycemia, drug-induced causes)
  • If on AED – compliance, PK (absorption, metabolism), increased dose needed?, change in medication needed?
31
Q

Outcome and expected time frame for monitoring efficacy

A
  • Seizure frequency/ severity
  • Daily by pt and at follow-ups
  • Improvement = 1-2 weeks
  • Significant benefit = 1 month
32
Q

Outcome and expected time frame for monitoring safety

A
  • Dose-dependent CNS effects (sedation, ataxia) – daily by pt and at follow-up; pharmacist to follow-up by phone after about 1 week
  • AED-specific effects (ex: rash, liver toxicity) – daily by pt and pharmacist follow-up; blood work drug dependent
33
Q

Outcome and expected time frame for monitoring convenience

A
  • Dose and titration schedule – for most q1-2weeks; escalate dose based on tolerability
  • Therapeutic drug monitoring – if indicated (ex: at 1 week and q3days for dose changes)
  • CBC, LFT, electrolytes – baseline and q3-6months initially
34
Q

Guidelines for d/c of AEDs

A
  • Seizure free period of >/ 2 years implies overall > 60% chance of successful withdrawal in some epilepsy syndromes
  • Favourable factors:
    • Control achieved easily on one drug at low dose
    • No previous unsuccessful attempts at withdrawal
    • Normal neurologic exam and EEG
  • Consider relative risk/ benefit (driving, pregnancy, toxicity vs. psychosocial/ vocational consequences of seizure)
  • To be done slowly – at least 2-3 months, one drug at a time
35
Q

Status epilepticus

A
  • Any seizure lasting > 30 mins +/- impaired consciousness, OR
  • Recurrent seizures w/o period of consciousness between seizures
  • Neurologic emergency
    • Associated w/ brain damage, tx resistance, and death
    • Poorer outcomes increase w/ increased seizure duration
  • Immediate emergency care if:
    • Seizure lasting > 5 mins
    • Repeated convulsive seizures (3 or more in 1 h)
36
Q

Status epilepticus supportive tx

A
  • Pt stabilization
  • Adequate oxygenation
  • Preservation of cardiorespiratory function
  • Management of systemic complications
  • Aggressive assessment of underlying causes
37
Q

Status epilepticus abortive tx

A
  • BZD (lorazepam, diazepam; buccal midazolam if IV not available)
    • 1st line for active seizures including SE
    • Effective in terminating seizures in 75-90% of px
  • Anticonvulsant (phenobarbital, phenytoin)
    • 2nd line if BZD doesn’t terminate seizure